Since 2001 he has been working at the National Institute of Mental Health (formerly the Psychiatric Centre in Prague), where he started preclinical research on the neurobiology of schizophrenia in pharmacological models of psychosis. He soon shifted his focus to research on the neurobiology of the effects of psychedelics (LSD, psilocin, 2C-B, mescaline, etc.) and entactogens (the drug ecstasy or MDMA) and new synthetic drugs. In parallel with his postgraduate research, he completed his clinical training in psychiatry and acquired functional expertise in electroencephalography (EEG). He defended his doctoral thesis in 2009 and obtained functional specialisation in psychiatry in 2012. Over the last decade, he has led or participated in a number of clinical trials with ketamine, psilocybin, ayahuasca and MDMA, both as principal investigator and as co-investigator. Until recently, he was principal investigator on a number of grants on psychedelics. In 2022 he became the head of the Psychedelics Research Centre at the National Institute of Mental Health in the Czech Republic. His current main research interests are clinical trials with psychedelics, translational research and neuroimaging studies with EEG.